These results revealed 10 potential biomarkers reflecting disease progression in BMD and suggest that BMD progression monitoring biomarkers are more likely found to be proteins involved in the innate immune response (C4BPB, PGLYRP2, GSN, CFI, C3, HPX and APCS), extracellular matrix organization (PLGLB1/ PLGLB2 and TNXB) and hemostasis (CLEC3B), than among muscle leakage proteins, which have been associated with disease progression in DMD patients. The gene discussed is PGLYRP2; the disease is Duchenne muscular dystrophy.